United Health Products, Inc. (OTC: UEEC) (UHP or the company) today announced that it is proceeding with its Premarket Approval (PMA) application for Class III approval to the FDA for HemoStyp®. In this current difficult environment, UHP has been working continuously with the FDA to advance its application, and has been working towards commercialization in anticipation of FDA approval.
Separately, the company announced that it is progressing in its negotiations with well positioned candidates interested in acquisition of the company or partnerships that allow penetration into the surgical markets.
About United Health Products
United Health Products develops technology; manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from oxidized regenerated cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
United Health Products, Inc.